Nipro Corporation
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NPRRF research report →
Companywww.nipro.co.jp
Nipro Corporation, together with its subsidiaries, engages in the medical devices, pharmaceuticals, and pharma packaging businesses. The company's Medical Device business develops, manufactures, and sells medical equipment for injection-infusion and dialysis treatment, and products related to diabetes and cell cultures, as well as the sale of artificial organ-related products. Its Pharmaceutical business provides pharmaceutical combination products, including dual chamber bags, pre-filled syringes, and half-type kits; and contract manufacturing services for orally administered drugs, injectables, and external preparations, as well as logistic and distribution services.
- CEO
- Yoshihiko Sano
- IPO
- 2018
- Employees
- 36,259
- HQ
- Osaka, JP
Price Chart
Valuation
- Market Cap
- $1.62B
- P/E
- 20.85
- P/S
- 0.43
- P/B
- 1.03
- EV/EBITDA
- 8.11
- Div Yield
- 1.68%
Profitability
- Gross Margin
- 31.53%
- Op Margin
- 5.70%
- Net Margin
- 2.04%
- ROE
- 5.37%
- ROIC
- 1.98%
Performance & Tape
- 52W High
- $9.96
- 52W Low
- $8.23
- 50D MA
- $9.96
- 200D MA
- $8.71
- Beta
- -0.57
- Avg Volume
- 8
Get TickerSpark's AI analysis on NPRRF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our NPRRF Coverage
We haven't published any research on NPRRF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NPRRF Report →